EyePoint Pharmaceuticals, Inc., a Delaware-based company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission on August 8, 2024. The filing is for the registration of additional shares available for issuance under various company plans. Specifically, 4,000,000 shares of common stock are being registered for the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan, and 250,000 shares for the 2019 Employee Stock Purchase Plan. Additionally, 466,400 shares are being registered for the issuance upon the exercise of nonqualified stock option awards granted as inducement for employment in compliance with Nasdaq Listing Rule 5635(c)(4). These Inducement Awards were approved by the company's Compensation Committee and are outside of the aforementioned plans. The Registration Statement incorporates by reference several of the company's previously filed documents, including annual and quarterly reports, and specifies that the company will provide the documents containing Part I information to participants as required.

EyePoint Pharmaceuticals, Inc., a Delaware-based company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission on August 8, 2024. The filing is for the registration of additional shares available for issuance under various company plans. Specifically, 4,000,000 shares of common stock are being registered for the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan, and 250,000 shares for the 2019 Employee Stock Purchase Plan. Additionally, 466,400 shares are being registered for the issuance upon the exercise of nonqualified stock option awards granted as inducement for employment in compliance with Nasdaq Listing Rule 5635(c)(4). These Inducement Awards were approved by the company's Compensation Committee and are outside of the aforementioned plans. The Registration Statement incorporates by reference several of the company's previously filed documents, including annual and quarterly reports, and specifies that the company will provide the documents containing Part I information to participants as required.